Streamline Health Solutions (STRM) 10-Q 20 Dec 24 2025 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Oct. 31, 2024	Dec. 16, 2024
Document Information [Line Items]
Entity Central Index Key	0001008586
Entity Registrant Name	STREAMLINE HEALTH SOLUTIONS INC.
Amendment Flag	false
Current Fiscal Year End Date	--01-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2025
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Oct. 31, 2024
Document Transition Report	false
Entity File Number	000-28132
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	31-1455414
Entity Address, Address Line One	2400 Old Milton Pkwy., Box 1353
Entity Address, City or Town	Alpharetta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30009
City Area Code	888
Local Phone Number	997-8732
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	STRM
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,273,175

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Oct. 31, 2024	Jan. 31, 2024
Current assets:
Cash and cash equivalents	$ 754,000	$ 3,190,000
Accounts receivable, net of allowance for credit losses of $59,000 and $86,000, respectively	2,824,000	4,237,000
Contract receivables	1,248,000	780,000
Prepaid and other current assets	567,000	629,000
Total current assets	5,393,000	8,836,000
Non-current assets:
Property and equipment, net of accumulated amortization of $328,000 and $291,000 respectively	52,000	88,000
Capitalized software development costs, net of accumulated amortization of $9,368,000 and $7,960,000, respectively	5,165,000	5,798,000
Intangible assets, net of accumulated amortization of $5,246,000 and $4,019,000, respectively	10,844,000	12,071,000
Goodwill	13,276,000	13,276,000
Other	1,236,000	1,666,000
Total non-current assets	30,573,000	32,899,000
Total assets	35,966,000	41,735,000
Current liabilities:
Accounts payable	1,610,000	1,253,000
Accrued expenses	1,518,000	2,023,000
Current portion of term loan	2,250,000	1,500,000
Deferred revenues	6,095,000	7,112,000
Acquisition earnout liability	377,000	1,794,000
Total current liabilities	11,850,000	13,682,000
Non-current liabilities:
Term loan, net of current portion and deferred financing costs	5,883,000	7,566,000
Line of credit	0	1,500,000
Notes payable, net of deferred financing costs	4,129,000	0
Deferred revenues, less current portion	190,000	173,000
Total non-current liabilities	10,202,000	9,239,000
Total liabilities	22,052,000	22,921,000
Commitments and contingencies – Note 8
Stockholders’ equity:
Common stock, $0.01 par value per share, 85,000,000 shares authorized; 4,265,821 and 3,929,446 shares issued and outstanding, respectively	43,000	39,000
Additional paid in capital	137,588,000	134,474,000
Accumulated deficit	(123,717,000)	(115,699,000)
Total stockholders’ equity	13,914,000	18,814,000
Total liabilities and stockholders’ equity	$ 35,966,000	$ 41,735,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Oct. 31, 2024	Jan. 31, 2024
Allowance for credit losses	$ 59,000	$ 86,000
Accumulated amortization	328,000	291,000
Capitalized software accumulated amortization	9,368,000	7,960,000
Intangible assets, accumulated amortization	$ 5,246,000	$ 4,019,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	85,000,000	85,000,000
Common stock, shares issued (in shares)	4,265,821	3,929,446
Common stock, shares outstanding (in shares)	4,265,821	3,929,446

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Statements of Operations - USD ($)		3 Months Ended		9 Months Ended
		Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2024	Oct. 31, 2023
Revenues:
Total revenues		$ 4,419,000	$ 6,133,000	$ 13,226,000	$ 17,235,000
Operating expenses:
Selling, general and administrative expense		2,880,000	4,122,000	9,060,000	12,079,000
Research and development		1,134,000	1,304,000	3,569,000	4,310,000
Impairment of goodwill		0	9,813,000	0	9,813,000
Impairment of long-lived assets		0	963,000	0	963,000
Total operating expenses		6,399,000	19,080,000	19,670,000	35,776,000
Operating loss		(1,980,000)	(12,947,000)	(6,444,000)	(18,541,000)
Other (expense) income:
Interest expense		(496,000)	(266,000)	(1,457,000)	(781,000)
Valuation adjustments		0	1,182,000	(115,000)	1,905,000
Other		0	0	(2,000)	31,000
Loss before income taxes		(2,476,000)	(12,031,000)	(8,018,000)	(17,386,000)
Income tax benefit		0	120,000	0	59,000
Net loss		$ (2,476,000)	$ (11,911,000)	$ (8,018,000)	$ (17,327,000)
Basic and Diluted Earnings Per Share:
Net loss per common share – basic and diluted (in dollars per share)		$ (0.61)	$ (3.15)	$ (2.01)	$ (4.61)
Weighted average number of common shares – basic and diluted (in shares)	[1],[2]	4,055,268	3,780,689	3,981,406	3,756,420
Software as a Service [Member]
Revenues:
Total revenues		$ 2,933,000	$ 3,924,000	$ 8,734,000	$ 10,630,000
Operating expenses:
Cost of goods and services		1,512,000	1,677,000	4,356,000	5,159,000
Maintenance [Member]
Revenues:
Total revenues		878,000	1,070,000	2,651,000	3,327,000
Operating expenses:
Cost of goods and services		42,000	129,000	127,000	250,000
Professional Fees and Licenses [Member]
Revenues:
Total revenues		608,000	1,139,000	1,841,000	3,278,000
Operating expenses:
Cost of goods and services		$ 831,000	$ 1,072,000	$ 2,558,000	$ 3,202,000
[1]Diluted net loss per share excludes the effect of shares that are anti-dilutive. For the three and nine months ended October 31, 2024, diluted earnings per share excludes 4,396 outstanding stock options, 220,327 unvested restricted shares of common stock, and 237,027 shares of common stock issuable through the exercise of warrants. For the three and nine months ended October 31, 2023, diluted earnings per share excludes 27,919 outstanding stock options and 132,013 unvested restricted shares of common stock.[2]Includes the effect of vested and excludes the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of October 31, 2024 and 2023, there were 220,327 and 132,013 unvested restricted shares of common stock outstanding, respectively.

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Statements of Stockholders' Equity - USD ($)	Cumulative Effect, Period of Adoption, Adjustment [Member] Common Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member] Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member] Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) (Accounting Standards Update 2016-13 [Member]) at Jan. 31, 2023	0
Balance (in shares) at Jan. 31, 2023					3,837,560
Balance (Accounting Standards Update 2016-13 [Member]) at Jan. 31, 2023	$ 0	$ 0	$ 36,000	$ 36,000
Balance at Jan. 31, 2023					$ 38,000	$ 132,511,000	$ (97,038,000)	$ 35,511,000
Restricted stock issued (in shares)					79,061
Restricted stock issued					$ 1,000	(1,000)	0	0
Restricted stock forfeited (in shares)					(1,893)
Restricted stock forfeited					$ 0	0	0	0
Surrender of shares (in shares)					(5,888)
Surrender of shares					$ 0	(179,000)	0	(179,000)
Share-based compensation					0	595,000	0	595,000
Net loss					$ 0	0	(2,901,000)	(2,901,000)
Balance (in shares) at Apr. 30, 2023					3,908,840
Balance at Apr. 30, 2023					$ 39,000	132,926,000	(99,903,000)	33,062,000
Balance (in shares) (Accounting Standards Update 2016-13 [Member]) at Jan. 31, 2023	0
Balance (in shares) at Jan. 31, 2023					3,837,560
Balance (Accounting Standards Update 2016-13 [Member]) at Jan. 31, 2023	$ 0	$ 0	$ 36,000	$ 36,000
Balance at Jan. 31, 2023					$ 38,000	132,511,000	(97,038,000)	35,511,000
Net loss								(17,327,000)
Balance (in shares) at Oct. 31, 2023					3,919,345
Balance at Oct. 31, 2023					$ 39,000	134,041,000	(114,329,000)	19,751,000
Balance (in shares) at Apr. 30, 2023					3,908,840
Balance at Apr. 30, 2023					$ 39,000	132,926,000	(99,903,000)	33,062,000
Restricted stock issued (in shares)					25,714
Restricted stock issued					$ 0	0	0	0
Restricted stock forfeited (in shares)					(5,133)
Restricted stock forfeited					$ 0	0	0	0
Surrender of shares (in shares)					(3,337)
Surrender of shares					$ 0	(73,000)	0	(73,000)
Share-based compensation					0	630,000	0	630,000
Net loss					$ 0	0	(2,515,000)	(2,515,000)
Balance (in shares) at Jul. 31, 2023					3,926,084
Balance at Jul. 31, 2023					$ 39,000	133,483,000	(102,418,000)	31,104,000
Restricted stock issued (in shares)					11,736
Restricted stock issued					$ 0	0	0	0
Restricted stock forfeited (in shares)					(15,940)
Restricted stock forfeited					$ 0	0	0	0
Surrender of shares (in shares)					(2,535)
Surrender of shares					$ 0	(19,000)	0	(19,000)
Share-based compensation					0	577,000	0	577,000
Net loss					$ 0	0	(11,911,000)	(11,911,000)
Balance (in shares) at Oct. 31, 2023					3,919,345
Balance at Oct. 31, 2023					$ 39,000	134,041,000	(114,329,000)	19,751,000
Balance (in shares) at Jan. 31, 2024					3,929,446
Balance at Jan. 31, 2024					$ 39,000	134,474,000	(115,699,000)	18,814,000
Restricted stock issued (in shares)					81,000
Restricted stock issued					$ 1,000	(1,000)	0	0
Restricted stock forfeited (in shares)					(3,224)
Restricted stock forfeited					$ 0	0	0	0
Surrender of shares (in shares)					(9,273)
Surrender of shares					$ 0	(67,000)	0	(67,000)
Share-based compensation					$ 0	529,000	0	529,000
Issuance of common stock (in shares)					123,502
Issuance of common stock					$ 1,000	769,000	0	770,000
Offering expenses					0	(4,000)	0	(4,000)
Net loss					$ 0	0	(2,739,000)	(2,739,000)
Balance (in shares) at Apr. 30, 2024					4,121,451
Balance at Apr. 30, 2024					$ 41,000	135,700,000	(118,438,000)	17,303,000
Balance (in shares) at Jan. 31, 2024					3,929,446
Balance at Jan. 31, 2024					$ 39,000	134,474,000	(115,699,000)	18,814,000
Net loss								(8,018,000)
Balance (in shares) at Oct. 31, 2024					4,265,821
Balance at Oct. 31, 2024					$ 43,000	137,588,000	(123,717,000)	13,914,000
Balance (in shares) at Apr. 30, 2024					4,121,451
Balance at Apr. 30, 2024					$ 41,000	135,700,000	(118,438,000)	17,303,000
Restricted stock issued (in shares)					113,769
Restricted stock issued					$ 1,000	(1,000)	0	0
Restricted stock forfeited (in shares)					(18,817)
Restricted stock forfeited					$ 0	0	0	0
Surrender of shares (in shares)					(3,452)
Surrender of shares					$ 0	(10,000)	0	(10,000)
Share-based compensation					0	571,000	0	571,000
Net loss					$ 0	0	(2,803,000)	(2,803,000)
Cashless exercise of warrants (in shares)					7,317
Cashless exercise of warrants					$ 0	0	0	0
Warrant liability reclassification					$ 0	837,000	0	837,000
Balance (in shares) at Jul. 31, 2024					4,220,268
Balance at Jul. 31, 2024					$ 42,000	137,097,000	(121,241,000)	15,898,000
Restricted stock issued (in shares)					54,801
Restricted stock issued					$ 1,000	(1,000)	0	0
Restricted stock forfeited (in shares)					(8,445)
Restricted stock forfeited					$ 0	0	0	0
Surrender of shares (in shares)					(803)
Surrender of shares					$ 0	0	0	0
Share-based compensation					0	492,000	0	492,000
Net loss					$ 0	0	(2,476,000)	(2,476,000)
Balance (in shares) at Oct. 31, 2024					4,265,821
Balance at Oct. 31, 2024					$ 43,000	$ 137,588,000	$ (123,717,000)	$ 13,914,000

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Net loss	$ (8,018,000)	$ (17,327,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,594,000	3,264,000
Accrued interest expense - notes payable	507,000	0
Valuation adjustments	115,000	(1,905,000)
Benefit for deferred income taxes	0	(104,000)
Share-based compensation expense	1,483,000	1,626,000
Impairment of goodwill	0	9,813,000
Impairment of long-lived assets	0	963,000
Provision for credit losses	(58,000)	0
Changes in assets and liabilities:
Accounts and contract receivables	1,003,000	4,299,000
Other assets	(116,000)	(65,000)
Accounts payable	357,000	109,000
Accrued expenses and other liabilities	(505,000)	(417,000)
Deferred revenue	(1,000,000)	(2,417,000)
Net cash used in operating activities	(2,638,000)	(2,161,000)
Cash flows from investing activities:
Purchases of property and equipment	0	(47,000)
Capitalization of software development costs	(667,000)	(1,562,000)
Net cash used in investing activities	(667,000)	(1,609,000)
Cash flows from financing activities:
Repayment of bank term loan	(1,000,000)	(500,000)
Repayment of line of credit	(1,500,000)	0
Proceeds from issuance of common stock	100,000	0
Proceeds from notes payable	4,400,000	0
Proceeds from line of credit	0	500,000
Payments of acquisition earnout liabilities	(886,000)	0
Payments for deferred financing costs	(168,000)	0
Repurchase of common shares to satisfy employee tax withholding	(77,000)	(271,000)
Net cash provided (used in) by financing activities	869,000	(271,000)
Net decrease in cash and cash equivalents	(2,436,000)	(4,041,000)
Cash and cash equivalents at beginning of period	3,190,000	6,598,000
Cash and cash equivalents at end of period	$ 754,000	$ 2,557,000

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation	9 Months Ended
	Oct. 31, 2024
Notes to Financial Statements
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	1 — BASIS OF PRESENTATION Streamline Health Solutions, Inc. and each of its wholly-owned subsidiaries, Streamline Health, LLC, Avelead Consulting, LLC, Streamline Consulting Solutions, LLC and Streamline Pay & Benefits, LLC, (collectively, unless the context requires otherwise, “we,” “us,” “our,” “Streamline,” or the “Company”), operate in one The accompanying unaudited condensed consolidated financial statements have been prepared by us pursuant to the rules and regulations applicable to quarterly reports on Form 10 not 10 three nine October 31, 2024 not may January 31, 2025. The Company has one operating segment and one reporting unit due to the singular nature of our products, product development and distribution process, and client base as a provider of computer software-based solutions and services for acute-care healthcare providers. All amounts in the condensed consolidated financial statements, notes and tables have been rounded to the nearest thousand dollars, except share and per share amounts, unless otherwise indicated. All references to a fiscal year refer to the fiscal year commencing February 1 January 31 Going Concern The Company’s financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of obligations in the normal course of business. To date, the Company has not twelve may not twelve one In view of these matters, continuation as a going concern is dependent upon the Company’s ability to achieve cash from operations and raise additional debt or equity capital to fund its ongoing operations. As of October 31, 2024 no The financial statements do not may not Reverse Stock Split On September 25, 2024, 1 12:01 October 4, 2024, one October 4, 2024. The Reverse Stock Split did not not January 31, 2024 No not

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Oct. 31, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Our significant accounting policies are presented in “Note 2 10 2023. 10 Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates and judgments, including those related to the recognition of revenue, share-based compensation, capitalization of software development costs, intangible assets, the allowance for credit losses, contingent consideration, and income taxes. Actual results could differ from those estimates. Fair Value of Financial Instruments The Financial Accounting Standards Board’s (“FASB”) authoritative guidance on fair value measurements establishes a framework for measuring fair value. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one three Level 1: Level 2: Level 3: not The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments. Cash and cash equivalents are classified as Level 1. 3 April 30, 2024. The table below provides information on the fair value of our liabilities on a recurring basis: Quoted Significant Prices in Other Significant Active Observable Unobservable Total Fair Markets Inputs Inputs Value (Level 1) (Level 2) (Level 3) At January 31, 2024 Acquisition earnout liability (1) $ 1,794,000 $ — $ — $ 1,794,000 ( 1 On March 27, 2024, 3 no 3 3. The table below provides the Level 3 nine October 31, 2024 no 3 three October 31, 2024 Nine-months ended October 31, 2024 Beginning balance $ 1,794,000 Settlement – common stock (690,000 ) Settlement – cash (447,000 ) Realized loss 159,000 Transfer out (817,000 ) Ending balance $ — The value of the Company’s acquisition earnout liability at October 31, 2024 October 31, 2024. The fair value of the Company’s term loan under its Second Amended and Restated Loan and Security Agreement (as amended and modified, the “Second Amended and Restated Loan Agreement”) was determined through an analysis of the interest rate spread from the date of closing the loan ( August 2021) October 31, 2024 January 31, 2024 October 31, 2024 January 31, 2024, 2 The estimated fair value of the Company’s notes payable under its private placement notes payables was determined through an analysis of the interest rate spread from the date of closing of the private placement ( February 7, 2024) October 31, 2024. 30 1 10 February 7, 2024 ( 30 October 31, 2024 2 The estimated fair value of the warrant liability is calculated using a Black-Scholes pricing model. The model input uses the warrant strike prices of $5.70 and $5.85, market prices on the measurement dates ($5.10 as of February 7, 2024, April 30, 2024, May 7, 2024) 48 Using this methodology, the Company recorded an opening warrant liability of $881,000 as of February 7, 2024. April 30, 2024 May 7, 2024 nine October 31, 2024. three October 31, 2024. May 7, 2024, Revenue Recognition We derive revenue from the sale of internally-developed software, either by licensing for local installation or by a SaaS delivery model, through the Company’s direct sales force or through third We recognize revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers may Disaggregation of Revenue The following table provides information about disaggregated revenue by type and nature of revenue stream: Three Months Ended Nine Months Ended October 31, 2024 October 31, 2023 October 31, 2024 October 31, 2023 Over time revenue $ 4,419,000 $ 6,133,000 $ 13,091,000 $ 17,161,000 Point in time revenue — — 135,000 74,000 Total revenue $ 4,419,000 $ 6,133,000 $ 13,226,000 $ 17,235,000 The Company includes revenue categories of (i) SaaS, (ii) maintenance and support, (iii) professional services, and (iv) audit services as over time revenue. For point in time revenue, the performance obligation is recognized as the point in time when the obligation is fully satisfied. The Company includes software licenses as point in time revenue. Contract Receivables and Deferred Revenues The Company receives payments from customers based upon contractual billing schedules. Contract receivables include amounts related to the Company’s contractual right to consideration for completed performance obligations not . During the three nine October 31, 2024 , the Company recognized approximately $ and $5,878,000, respectively, in revenue from deferred revenues outstanding as of January 31, 2024 . October 31, 2024 Deferred costs (costs to fulfill a contract and contract acquisition costs) The Company defers th e direct costs, which include salaries and benefits, for professional services related to SaaS contracts as a cost to fulfill a contract. These deferred costs will be amortized on a straight-line basis over the period of expected benefit which is the contractual term. As of October 31, 2024 and January 31, 2024 , the Company had deferred costs of $68,000 and $77,000, r on of $147,000 and $102,000, r s $44,000 and $59,000 fo nine October 31, 2024 2023 three October 31, 2024 2023 of $11,000 Contract acquisition costs, which consist of sales commissions paid or payable, are considered incremental and recoverable costs of obtaining a contract with a customer. Sales commissions for initial and renewal contracts are deferred and then amortized on a straight-line basis over the contract term. As a practical expedient, the Company expenses sales commissions as incurred when the amortization period of related deferred commission costs is expected to be one As of October 31, 2024 and January 31, 2024 , deferred commission costs paid and payable, which are included on the consolidated balance sheets within other non-current assets totaled $1,157,000 and $1,461,000 $141,000 and $129,000 fo three October 31, 2024 2023 , respectively. For the nine October 31, 2024 2023 s was $450,000 $38 3,000 three nine October 31, 2024, three nine October 31, 2023, Allowance for Credit Losses The Company estimates current expected credit losses based on historical credit loss rates and applied an increase to account for future economic conditions. The changes in the Company’s allowance for credit losses is as follows: January 31, 2024 CECL Adoption Provision adjustments Write-offs & Recoveries October 31, 2024 Allowance for credit losses $ 86,000 $ — (58,000 ) 31,000 $ 59,000 January 31, 2023 CECL Adoption Provision adjustments Write-offs & Recoveries October 31, 2023 Allowance for credit losses $ 132,000 $ (36,000 ) $ — $ — $ 96,000 Equity Awards The Company accounts for share-based payments based on the grant-date fair value of the awards with compensation cost recognized as expense over the requisite service period, and forfeitures are recognized as incurred. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the entity had paid cash for the goods or services. The Company incurred total compensation expense related to share-based awards for the three nine October 31, 2024 three nine October 31, 2023 The fair value of stock options granted are estimated at the date of grant using a Black-Scholes option pricing model. Option pricing model input assumptions such as expected term, expected volatility and risk-free interest rate impact the fair value estimate. These assumptions are subjective and are generally derived from external (such as, risk-free rate of interest) and historical data (such as, volatility factor and expected term). Future grants of equity awards accounted for as share-based compensation could have a material impact on reported expenses depending upon the number, value and vesting period of future awards. The Company issues restricted stock awards in the form of Company common stock. The fair value of these awards is based on the market closing price per share on the grant date. For the three nine October 31, 2024 three nine October 31, 2023 Market-Based Awards For awards with a market condition, the Company adjusts the grant date fair value for the condition. The Company used separate Monte Carlo valuation models, as of the grant date, to determine the expected length and fair value of this particular award. Both models used the Company's historical equity volatility, current stock price, and hurdle target price for vesting. The service period model also included an assumption for the Company's 10 On July 18, 2024, On September 4, 2024, no July 18, 2025. Warrants The Company reviews the specific terms for its warrants and applies the authoritative FASB guidance under ASC topics 480 , 480” 815 , 815” 480 , 480 , 815 , For the issued or modified warrants that qualify for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for tax credit and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing net deferred tax assets, the Company considers whether it is more likely than not not not not 6 The Company provides for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether certain tax positions are more likely than not October 31, 2024 Net Loss Per Common Share The Company presents basic and diluted earnings per share (“EPS”) data for the Company’s common stock. The Company’s warrants, unvested restricted stock awards, and options are considered non-participating securities because holders are not The following is the calculation of the basic and diluted net loss per share of common stock for the three nine October 31, 2024 2023 Three Months Ended Nine Months Ended October 31, 2024 October 31, 2023 October 31, 2024 October 31, 2023 Basic and diluted loss per share: Net loss $ (2,476,000 ) $ (11,911,000 ) $ (8,018,000 ) $ (17,327,000 ) Basic and diluted net loss per share of common stock $ (0.61 ) $ (3.15 ) $ (2.01 ) $ (4.61 ) Weighted average shares outstanding – basic and diluted (1)(2) 4,055,268 3,780,689 3,981,406 3,756,420 ( 1 Includes the effect of vested and excludes the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of October 31, 2024 2023 and 132,013 ( 2 Diluted net loss per share excludes the effect of shares that are anti-dilutive. For the three nine October 31, 2024 three nine October 31, 2023 Restructuring On October 16, 2023, one 2023. nine October 31, 2024 (in thousands) As of October 31, 2024 Accrued Balance as of 2024 2024 Accrued Balance as of Total Costs Total January 31, 2024 Expenses to Date Cash Payments October 31, 2024 Incurred to Date Expected Costs Severance expense Cost of sales $ — $ — $ — $ — $ 154 $ 154 Selling, general, and administrative 74 — (74 ) — 350 350 Research and development — — — — 227 227 Total severance expense $ 74 $ — $ (74 ) $ — $ 731 $ 731 Professional fees — — — — 28 28 Total $ 74 $ — $ (74 ) $ — $ 759 $ 759 (in thousands) Accrued Balance as of 2023 2023 Accrued Balance as of January 31, 2023 Expenses to Date Cash Payments October 31, 2023 Severance expense Cost of sales $ — $ 154 $ — $ 154 Selling, general, and administrative — 350 — 350 Research and development — 227 — 227 Total severance expense $ — $ 731 $ — $ 731 Professional fees — 18 — 18 Total $ — $ 749 $ — $ 749 Non-Cash Items For the three nine October 31, 2024 2023 For the nine October 31, 2024 second 5 2023, 7 not nine October 31, 2023. Recent Accounting Pronouncements Not In November 2023, 2023 07, 280 2023 07 December 15, 2023, December 15, 2024. 2023 07 January 31, 2025. not In December 2023, 2023 09, 740 2023 09 December 15, 2024. not In November 2024, 2024 03, 220 40 2024 03 December 15, 2026, December 15, 2027. not

Note 3 - Business Combination

Note 3 - Business Combination	9 Months Ended
	Oct. 31, 2024
Notes to Financial Statements
Business Combination Disclosure [Text Block]	NOTE 3 — BUSINESS COMBINATION Avelead Acquisition The Company acquired all the equity interests of Avelead Consulting, LLC (“Avelead”) as part of the Company’s strategic expansion into the acute-care health care revenue cycle management industry (the “Transaction”). The Transaction was completed on August 16, 2021. As of January 31, 2024, second March 27, 2024, second three nine October 31, 2024 second October 31, 2024. October 31, 2024

Note 4 - Operating Leases

Note 4 - Operating Leases	9 Months Ended
	Oct. 31, 2024
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	NOTE 4 — OPERATING LEASES We determine whether an arrangement is a lease at inception. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the expected lease term. Since our lease arrangements do not The Company has moved to a virtual office model and does not three nine October 31, 2024 2023 Alpharetta Office Lease On October 1, 2021, third not not March 31, 2023. nine October 31, 2024 2023 three October 31, 2024 2023 The Company entered into a lease for office space in Alpharetta, Georgia, on March 1, 2020. March 31, 2023. nine October 31, 2024 2023 three October 31, 2024 2023 Suwanee Office Lease Upon acquiring Avelead on August 16, 2021 ( 3 one March 1, 2019, February 28, 2022. February 28, 2023, not nine October 31, 2024 2023 three October 31, 2024 2023

Note 5 - Debt

Note 5 - Debt	9 Months Ended
	Oct. 31, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 5 — DEBT Outstanding principal balances consisted of the following at October 31, 2024 October 31, 2024 January 31, 2024 Term loan $ 8,000,000 $ 9,000,000 Financing cost payable 177,000 135,000 Less: Deferred financing cost (44,000 ) (69,000 ) Total 8,133,000 9,066,000 Less: Current portion of term loan (2,250,000 ) (1,500,000 ) Non-current portion of term loan $ 5,883,000 $ 7,566,000 October 31, 2024 January 31, 2024 Notes payable and accrued interest $ 4,907,000 $ — Less: Discount on notes payable (642,000 ) — Less: Deferred financing costs (136,000 ) — Total 4,129,000 — Less: Current portion of notes payable — — Non-current portion of notes payable $ 4,129,000 $ — Term Loan and Revolving Line of Credit On November 29, 2022, August 26, 2026. Prime Rate Under the Second Amended and Restated Loan Agreement, the Company has a term loan facility with an initial maximum principal amount of $10,000,000. Amounts outstanding under the Second Amended and Restated Loan Agreement bear interest at a per annum rate equal to the Prime Rate (as published in The Wall Street Journal) plus 1.5%, with a Prime “floor” rate of 3.25%. The Second Amended and Restated Loan Agreement has a five August 2021). one second third fourth fifth may The Company executed a Third Modification and Waiver to Second Amended and Restated Loan Agreement (the “Third Modification”) and a Fourth Modification to Second Amended and Restated Loan Agreement (the “Fourth Modification”) on February 7, 2024 April 5, 2024, ● Minimum Adjusted EBITDA January 31, 2024, not no Minimum Quarter Ending Adjusted EBITDA January 31, 2024 $ (5,750,000 ) April 30, 2024 (4,560,000 ) July 31, 2024 (2,960,000 ) October 31, 2024 (1,500,000 ) January 31, 2025 430,000 ● Maximum ARR Net Leverage Ratio not Maximum ARR Net Leverage Quarter Ending Ratio April 30, 2024 0.50 to 1.00 July 31, 2024 0.45 to 1.00 October 31, 2024 0.40 to 1.00 January 31, 2025 0.35 to 1.00 ● Maximum Debt to Adjusted EBITDA Ratio April 30, 2025, four 4 not Maximum Debt to Adjusted EBITDA Quarter Ending Ratio April 30, 2025 3.50 to 1.00 July 31, 2025 3.00 to 1.00 October 31, 2025 2.50 to 1.00 January 31, 2026 and on the last day of each quarter thereafter 2.00 to 1.00 ● Fixed Charge Coverage Ratio April 30, 2025, not 1.00, four 4 On November 13, 2024, 11 The Second Amended and Restated Loan Agreement also includes customary negative covenants, subject to exceptions, which limit transfers, capital expenditures, indebtedness, certain liens, investments, acquisitions, dispositions of assets, restricted payments, and the business activities of the Company, as well as customary representations and warranties, affirmative covenants and events of default, including a cross default provision with the Second Amended and Restated Loan Agreement and a change of control default provision. The line of credit also is subject to customary prepayment requirements. Substantially all the assets of the Company are collateralized by the Second Amended and Restated Loan Agreement. For the period ended October 31, 2024, not October 31, 2024, may not 1 The Company records costs related to the maintenance of the Second Amended and Restated Loan Agreement as deferred financing costs, net of the term loan. These deferred financing costs are being amortized over the remaining term of the loan. The Company has incurred $250,000 in financing costs which become payable at the earlier of the term date of the loan, or pre-payment. These costs are being accreted, through interest expense, to the full value of the $250,000 over the remaining term of the loan. Debt Private Placement On February 1, 2024, February 7, 2024 ( Notes Payable The Notes bear interest at a rate of 15% per annum and mature on August 7, 2026 ( may twelve 12 twelve 12 The Notes also include customary negative covenants, subject to exceptions, which limit dispositions of assets and the business activities of the Company, as well as customary representations and warranties, affirmative covenants and events of default, including a cross default provision with the Second Amended and Restated Loan Agreement and a change of control default provision. The rights of each Investor to receive payments under the Notes are subordinate to the rights of Western Alliance Bank (“WAB”), pursuant to a subordination agreement which the Investors entered into with WAB concurrently with the Debt Private Placement. The Company allocated the original total proceeds at inception from the Debt Private Placement and Common Stock Private Placement (refer to Note 7 Warrants The Warrants have an exercise price of $5.70 (except for Warrants issued to the Company’s directors and officers which have an exercise price of $5.85), are immediately exercisable, and will expire on the fourth The Notes and the Warrants described above were offered in a private placement under Section 4 2 1933, may not 501 The Warrants contain a registration rights provision for the Company to provide the Warrant holder with registered common stock upon their exercise of a Warrant. If the Company is not May 7, 2024, 3 No. 333 279190 No. 1 3 May 24, 2024 ( June 10, 2024. The Company allocated the total proceeds from the Debt Private Placement and Common Stock Private Placement (refer to Note 7 three July 31, 2024, $837,000

Note 6 - Income Taxes

Note 6 - Income Taxes	9 Months Ended
	Oct. 31, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 6 — INCOME TAXES Income tax expense was $0 for the nine October 31, 2024 The Company has recorded $346,000 and $340,000 in reserves for uncertain tax positions as of October 31, 2024 January 31, 2024 The Company and its subsidiaries are subject to U.S. federal income tax as well as income taxes in multiple state and local jurisdictions. The Company has concluded all U.S. federal tax matters for years through January 31, 2020. January 31, 2019. no January 31, 2020; January 31, 2020, may

Note 7 - Equity

Note 7 - Equity	9 Months Ended
	Oct. 31, 2024
Notes to Financial Statements
Equity [Text Block]	NOTE 7 — EQUITY Common Stock Private Placement On February 6, 2024, The common stock described above was offered in a private placement under Section 4 2 not may not 501 The Company allocated the total proceeds of the Common Stock Private Placement across the underlying components. As a result, $77,000 of net proceeds, comprised of $81,000 of the proceeds less $4,000 of issuance costs, were recorded for the Common Stock Private Placement as equity. Registration of Shares Issued to 180 On June 28, 2023, 3 No. 333 272993 180 “180 July 10, 2023. On May 7, 2024, 3 No. 333 279190 No. 1 3 May 24, 2024, 180 June 10, 2024. 2024 At the 2024 June 13, 2024, 2024 “2024 2024 2013 “2013 2024 2024 The 2024 2024

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	9 Months Ended
	Oct. 31, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 8 — COMMITMENTS AND CONTINGENCIES Consulting Agreement with 180 On March 19, 2020, 180 180 September 20, 2021, December 2023, two October 31, 2024 three 20 90 no may 121G “121G” 121G, 180 nine October 31, 2024 2023 October 31, 2024 three October 31, 2024 2023 180 180 three nine October 31, 2024 180 three nine October 31, 2023 three nine October 31, 2024 three nine October 31, 2023 180 three nine October 31, 2024 three nine October 31, 2023 180 Inclusive of the MSA executed with 180 180 121G. no 121G. 180 121G three nine October 31, 2024 2023 Litigation We are, from time to time, a party to various legal proceedings and claims, which arise in the ordinary course of business. We are not

Note 9 - Related Party Transact

Note 9 - Related Party Transactions	9 Months Ended
	Oct. 31, 2024
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 9 Avelead Office Lease The Company acquired Avelead on August 16, 2021. one August 2023. February 2023. nine October 31, 2024 2023 three October 31, 2024 2023 3 Debt Private Placement The following related parties participated in the Debt Private Placement (Refer to Note 5 Name of Investor Investment Amount Warrants Granted 121G, LLC (1) $ 1,000,000 59,829 Matthew W. Etheridge (2) 1,000,000 61,403 Jonathan R. Phillips (3) 50,000 2,991 The Ferayorni Family Trust (4) 500,000 29,914 ( 1 121G, “121G” may 121G. ( 2 3 4 may Common Stock Private Placement On February 6, 2024,

Note 10 - Goodwill and Intangib

Note 10 - Goodwill and Intangible Assets	9 Months Ended
	Oct. 31, 2024
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	NOTE 10 Goodwill represents the excess cost over fair value of the net assets of acquired businesses and is not fourth November 1, The Company’s intangible assets consist of client relationships, acquired and developed technology, and trade names. These assets are recorded at cost, less accumulated amortization and impairment, if any. All the Company’s intangible assets are definite lived and amortized on a straight-line basis over their estimated useful lives. Subsequent testing of intangible assets is conducted when a triggering event occurs that would indicate impairment may During the quarter ended October 31, 2024, “2024 2024 October 31, 2024. 360, 360” 350, 350” In October 2023, not December 31, 2023. October 16, 2023. “2023 2023 October 31, 2023. 360 350. Goodwill The Company has one reporting unit for purposes of evaluation of goodwill. Impairment testing was performed under the guidance of ASC 350 The MCM calculates the aggregate market value of the Company based on the total number of shares outstanding and the current market price of the shares as of the valuation date. Data on similar mergers and acquisitions within healthcare technology are observed to determine control premium that represents a stock premium percentage offered by an acquirer to a public company. The control premium applied to the aggregate market value represents MCM calculated fair value. The DCF incorporates the use of projected financial information and a discount rate using a weighted average cost of capital with cost of equity estimated based on the capital asset pricing model. The cash-flow projections are based on financial forecasts developed by management that include forecasts of future operating results based on internal budgets and strategic plans to invest in working capital to support anticipated revenue growth. External factors and business conditions are considered by management when setting the long-term growth rates. The selected discount rate considers the risk and nature of the reporting unit’s cash flows and the rates of return market participants would require to invest their capital in the Company. Based on the impairment test following the 2024 not October 31, 2024. 2023 October 31, 2023, nine October 31, 2023. The changes in the carrying amount of goodwill were as follows for the nine October 31, 2023: Nine Months Ended October 31, 2023 Balance as of January 31, 2023 $ 23,089,000 Impairment (9,813,000 ) Balance as of October 31, 2023 $ 13,276,000 Intangible Assets ASC 360 2023 three nine October 31, 2023, Next, the Company must review the long-lived assets to define asset group(s) that would reflect the lowest level of assets to which discrete cash flows are identifiable. In performing this review, the Company identified that the long-lived asset “client relationships” related to Avelead should be classified as abandoned (the “Abandoned Asset”) with the Company determining that it no zero no The Company determined the lowest level of discrete cash flows is at the reporting unit level, and all remaining long-lived assets (excluding the Abandoned Asset) and goodwill would represent its only asset group. Recoverability is assessed by comparing that the sum of the discrete undiscounted cash flows exceeds the carrying value of the asset group. The undiscounted cash flow projections are based on the primary asset in the asset group that include forecasts of future operating results based on internal budgets and strategic plans to investment in working capital to support anticipated revenue growth. The undiscounted cash flows for the long-lived assets were above the carrying amounts indicating that the long-lived asset group is recoverable and no October 31, 2023. three October 31, 2023, no three October 31, 2024.

Note 11 - Subsequent Events

Note 11 - Subsequent Events	9 Months Ended
	Oct. 31, 2024
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 11 Loan Modification On November 13, 2024, a. Maximum ARR Net Leverage Ratio September 30, 2024, not Maximum ARR Net Leverage Month Ending Ratio September 30, 2024 0.68 to 1.00 October 31, 2024 0.66 to 1.00 November 30, 2024 0.64 to 1.00 December 31, 2024 0.60 to 1.00 January 31, 2025 0.35 to 1.00 April 30, 2025 0.35 to 1.00 b. Minimum Adjusted EBITDA September 30, 2024, not no Minimum Month Ending Adjusted EBITDA September 30, 2024 $ (225,000 ) October 31, 2024 (500,000 ) November 30, 2024 (150,000 ) December 31, 2024 (100,000 ) January 31, 2025 and on the last day of each month thereafter through April 30, 2025 0 The Fifth Modification also requires the Company to pay certain fees to Western Alliance Bank in connection with the extension of credit and subsequent repayment of obligations due to Western Alliance Bank under the Second Amended and Restated Loan and Security Agreement. The foregoing fees, if any, will be due and payable on the earlier of (i) August 26, 2026, Line of Credit Draw On November 20, 2024, 5

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Oct. 31, 2024
Insider Trading Arr Line Items
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Oct. 31, 2024
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates and judgments, including those related to the recognition of revenue, share-based compensation, capitalization of software development costs, intangible assets, the allowance for credit losses, contingent consideration, and income taxes. Actual results could differ from those estimates.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The Financial Accounting Standards Board’s (“FASB”) authoritative guidance on fair value measurements establishes a framework for measuring fair value. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one three Level 1: Level 2: Level 3: not The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments. Cash and cash equivalents are classified as Level 1. 3 April 30, 2024. The table below provides information on the fair value of our liabilities on a recurring basis: Quoted Significant Prices in Other Significant Active Observable Unobservable Total Fair Markets Inputs Inputs Value (Level 1) (Level 2) (Level 3) At January 31, 2024 Acquisition earnout liability (1) $ 1,794,000 $ — $ — $ 1,794,000 ( 1 On March 27, 2024, 3 no 3 3. The table below provides the Level 3 nine October 31, 2024 no 3 three October 31, 2024 Nine-months ended October 31, 2024 Beginning balance $ 1,794,000 Settlement – common stock (690,000 ) Settlement – cash (447,000 ) Realized loss 159,000 Transfer out (817,000 ) Ending balance $ — The value of the Company’s acquisition earnout liability at October 31, 2024 October 31, 2024. The fair value of the Company’s term loan under its Second Amended and Restated Loan and Security Agreement (as amended and modified, the “Second Amended and Restated Loan Agreement”) was determined through an analysis of the interest rate spread from the date of closing the loan ( August 2021) October 31, 2024 January 31, 2024 October 31, 2024 January 31, 2024, 2 The estimated fair value of the Company’s notes payable under its private placement notes payables was determined through an analysis of the interest rate spread from the date of closing of the private placement ( February 7, 2024) October 31, 2024. 30 1 10 February 7, 2024 ( 30 October 31, 2024 2 The estimated fair value of the warrant liability is calculated using a Black-Scholes pricing model. The model input uses the warrant strike prices of $5.70 and $5.85, market prices on the measurement dates ($5.10 as of February 7, 2024, April 30, 2024, May 7, 2024) 48 Using this methodology, the Company recorded an opening warrant liability of $881,000 as of February 7, 2024. April 30, 2024 May 7, 2024 nine October 31, 2024. three October 31, 2024. May 7, 2024,
Revenue [Policy Text Block]	Revenue Recognition We derive revenue from the sale of internally-developed software, either by licensing for local installation or by a SaaS delivery model, through the Company’s direct sales force or through third We recognize revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers may Disaggregation of Revenue The following table provides information about disaggregated revenue by type and nature of revenue stream: Three Months Ended Nine Months Ended October 31, 2024 October 31, 2023 October 31, 2024 October 31, 2023 Over time revenue $ 4,419,000 $ 6,133,000 $ 13,091,000 $ 17,161,000 Point in time revenue — — 135,000 74,000 Total revenue $ 4,419,000 $ 6,133,000 $ 13,226,000 $ 17,235,000 The Company includes revenue categories of (i) SaaS, (ii) maintenance and support, (iii) professional services, and (iv) audit services as over time revenue. For point in time revenue, the performance obligation is recognized as the point in time when the obligation is fully satisfied. The Company includes software licenses as point in time revenue. Contract Receivables and Deferred Revenues The Company receives payments from customers based upon contractual billing schedules. Contract receivables include amounts related to the Company’s contractual right to consideration for completed performance obligations not . During the three nine October 31, 2024 , the Company recognized approximately $ and $5,878,000, respectively, in revenue from deferred revenues outstanding as of January 31, 2024 . October 31, 2024 Deferred costs (costs to fulfill a contract and contract acquisition costs) The Company defers th e direct costs, which include salaries and benefits, for professional services related to SaaS contracts as a cost to fulfill a contract. These deferred costs will be amortized on a straight-line basis over the period of expected benefit which is the contractual term. As of October 31, 2024 and January 31, 2024 , the Company had deferred costs of $68,000 and $77,000, r on of $147,000 and $102,000, r s $44,000 and $59,000 fo nine October 31, 2024 2023 three October 31, 2024 2023 of $11,000 Contract acquisition costs, which consist of sales commissions paid or payable, are considered incremental and recoverable costs of obtaining a contract with a customer. Sales commissions for initial and renewal contracts are deferred and then amortized on a straight-line basis over the contract term. As a practical expedient, the Company expenses sales commissions as incurred when the amortization period of related deferred commission costs is expected to be one As of October 31, 2024 and January 31, 2024 , deferred commission costs paid and payable, which are included on the consolidated balance sheets within other non-current assets totaled $1,157,000 and $1,461,000 $141,000 and $129,000 fo three October 31, 2024 2023 , respectively. For the nine October 31, 2024 2023 s was $450,000 $38 3,000 three nine October 31, 2024, three nine October 31, 2023, Allowance for Credit Losses The Company estimates current expected credit losses based on historical credit loss rates and applied an increase to account for future economic conditions. The changes in the Company’s allowance for credit losses is as follows: January 31, 2024 CECL Adoption Provision adjustments Write-offs & Recoveries October 31, 2024 Allowance for credit losses $ 86,000 $ — (58,000 ) 31,000 $ 59,000 January 31, 2023 CECL Adoption Provision adjustments Write-offs & Recoveries October 31, 2023 Allowance for credit losses $ 132,000 $ (36,000 ) $ — $ — $ 96,000
Share-Based Payment Arrangement [Policy Text Block]	Equity Awards The Company accounts for share-based payments based on the grant-date fair value of the awards with compensation cost recognized as expense over the requisite service period, and forfeitures are recognized as incurred. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the entity had paid cash for the goods or services. The Company incurred total compensation expense related to share-based awards for the three nine October 31, 2024 three nine October 31, 2023 The fair value of stock options granted are estimated at the date of grant using a Black-Scholes option pricing model. Option pricing model input assumptions such as expected term, expected volatility and risk-free interest rate impact the fair value estimate. These assumptions are subjective and are generally derived from external (such as, risk-free rate of interest) and historical data (such as, volatility factor and expected term). Future grants of equity awards accounted for as share-based compensation could have a material impact on reported expenses depending upon the number, value and vesting period of future awards. The Company issues restricted stock awards in the form of Company common stock. The fair value of these awards is based on the market closing price per share on the grant date. For the three nine October 31, 2024 three nine October 31, 2023 Market-Based Awards For awards with a market condition, the Company adjusts the grant date fair value for the condition. The Company used separate Monte Carlo valuation models, as of the grant date, to determine the expected length and fair value of this particular award. Both models used the Company's historical equity volatility, current stock price, and hurdle target price for vesting. The service period model also included an assumption for the Company's 10 On July 18, 2024, On September 4, 2024, no July 18, 2025.
Derivatives, Policy [Policy Text Block]	Warrants The Company reviews the specific terms for its warrants and applies the authoritative FASB guidance under ASC topics 480 , 480” 815 , 815” 480 , 480 , 815 , For the issued or modified warrants that qualify for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not
Income Tax, Policy [Policy Text Block]	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for tax credit and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing net deferred tax assets, the Company considers whether it is more likely than not not not not 6 The Company provides for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether certain tax positions are more likely than not October 31, 2024
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Common Share The Company presents basic and diluted earnings per share (“EPS”) data for the Company’s common stock. The Company’s warrants, unvested restricted stock awards, and options are considered non-participating securities because holders are not The following is the calculation of the basic and diluted net loss per share of common stock for the three nine October 31, 2024 2023 Three Months Ended Nine Months Ended October 31, 2024 October 31, 2023 October 31, 2024 October 31, 2023 Basic and diluted loss per share: Net loss $ (2,476,000 ) $ (11,911,000 ) $ (8,018,000 ) $ (17,327,000 ) Basic and diluted net loss per share of common stock $ (0.61 ) $ (3.15 ) $ (2.01 ) $ (4.61 ) Weighted average shares outstanding – basic and diluted (1)(2) 4,055,268 3,780,689 3,981,406 3,756,420 ( 1 Includes the effect of vested and excludes the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of October 31, 2024 2023 and 132,013 ( 2 Diluted net loss per share excludes the effect of shares that are anti-dilutive. For the three nine October 31, 2024 three nine October 31, 2023
Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]	Restructuring On October 16, 2023, one 2023. nine October 31, 2024 (in thousands) As of October 31, 2024 Accrued Balance as of 2024 2024 Accrued Balance as of Total Costs Total January 31, 2024 Expenses to Date Cash Payments October 31, 2024 Incurred to Date Expected Costs Severance expense Cost of sales $ — $ — $ — $ — $ 154 $ 154 Selling, general, and administrative 74 — (74 ) — 350 350 Research and development — — — — 227 227 Total severance expense $ 74 $ — $ (74 ) $ — $ 731 $ 731 Professional fees — — — — 28 28 Total $ 74 $ — $ (74 ) $ — $ 759 $ 759 (in thousands) Accrued Balance as of 2023 2023 Accrued Balance as of January 31, 2023 Expenses to Date Cash Payments October 31, 2023 Severance expense Cost of sales $ — $ 154 $ — $ 154 Selling, general, and administrative — 350 — 350 Research and development — 227 — 227 Total severance expense $ — $ 731 $ — $ 731 Professional fees — 18 — 18 Total $ — $ 749 $ — $ 749
Noncash Investing and Financing Activities [Policy Text Block]	Non-Cash Items For the three nine October 31, 2024 2023 For the nine October 31, 2024 second 5 2023, 7 not nine October 31, 2023.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Not In November 2023, 2023 07, 280 2023 07 December 15, 2023, December 15, 2024. 2023 07 January 31, 2025. not In December 2023, 2023 09, 740 2023 09 December 15, 2024. not In November 2024, 2024 03, 220 40 2024 03 December 15, 2026, December 15, 2027. not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Oct. 31, 2024
Notes Tables
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	Quoted Significant Prices in Other Significant Active Observable Unobservable Total Fair Markets Inputs Inputs Value (Level 1) (Level 2) (Level 3) At January 31, 2024 Acquisition earnout liability (1) $ 1,794,000 $ — $ — $ 1,794,000
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Nine-months ended October 31, 2024 Beginning balance $ 1,794,000 Settlement – common stock (690,000 ) Settlement – cash (447,000 ) Realized loss 159,000 Transfer out (817,000 ) Ending balance $ —
Disaggregation of Revenue [Table Text Block]	Three Months Ended Nine Months Ended October 31, 2024 October 31, 2023 October 31, 2024 October 31, 2023 Over time revenue $ 4,419,000 $ 6,133,000 $ 13,091,000 $ 17,161,000 Point in time revenue — — 135,000 74,000 Total revenue $ 4,419,000 $ 6,133,000 $ 13,226,000 $ 17,235,000
Accounting Standards Update and Change in Accounting Principle [Table Text Block]	January 31, 2024 CECL Adoption Provision adjustments Write-offs & Recoveries October 31, 2024 Allowance for credit losses $ 86,000 $ — (58,000 ) 31,000 $ 59,000 January 31, 2023 CECL Adoption Provision adjustments Write-offs & Recoveries October 31, 2023 Allowance for credit losses $ 132,000 $ (36,000 ) $ — $ — $ 96,000
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Nine Months Ended October 31, 2024 October 31, 2023 October 31, 2024 October 31, 2023 Basic and diluted loss per share: Net loss $ (2,476,000 ) $ (11,911,000 ) $ (8,018,000 ) $ (17,327,000 ) Basic and diluted net loss per share of common stock $ (0.61 ) $ (3.15 ) $ (2.01 ) $ (4.61 ) Weighted average shares outstanding – basic and diluted (1)(2) 4,055,268 3,780,689 3,981,406 3,756,420
Restructuring and Related Costs [Table Text Block]	(in thousands) As of October 31, 2024 Accrued Balance as of 2024 2024 Accrued Balance as of Total Costs Total January 31, 2024 Expenses to Date Cash Payments October 31, 2024 Incurred to Date Expected Costs Severance expense Cost of sales $ — $ — $ — $ — $ 154 $ 154 Selling, general, and administrative 74 — (74 ) — 350 350 Research and development — — — — 227 227 Total severance expense $ 74 $ — $ (74 ) $ — $ 731 $ 731 Professional fees — — — — 28 28 Total $ 74 $ — $ (74 ) $ — $ 759 $ 759 (in thousands) Accrued Balance as of 2023 2023 Accrued Balance as of January 31, 2023 Expenses to Date Cash Payments October 31, 2023 Severance expense Cost of sales $ — $ 154 $ — $ 154 Selling, general, and administrative — 350 — 350 Research and development — 227 — 227 Total severance expense $ — $ 731 $ — $ 731 Professional fees — 18 — 18 Total $ — $ 749 $ — $ 749

Note 5 - Debt (Tables)

Note 5 - Debt (Tables)	9 Months Ended
	Oct. 31, 2024
Notes Tables
Schedule of Debt [Table Text Block]	October 31, 2024 January 31, 2024 Term loan $ 8,000,000 $ 9,000,000 Financing cost payable 177,000 135,000 Less: Deferred financing cost (44,000 ) (69,000 ) Total 8,133,000 9,066,000 Less: Current portion of term loan (2,250,000 ) (1,500,000 ) Non-current portion of term loan $ 5,883,000 $ 7,566,000 October 31, 2024 January 31, 2024 Notes payable and accrued interest $ 4,907,000 $ — Less: Discount on notes payable (642,000 ) — Less: Deferred financing costs (136,000 ) — Total 4,129,000 — Less: Current portion of notes payable — — Non-current portion of notes payable $ 4,129,000 $ —
Schedule Of Minimum Adjusted EBITDA [Table Text Block]	Minimum Quarter Ending Adjusted EBITDA January 31, 2024 $ (5,750,000 ) April 30, 2024 (4,560,000 ) July 31, 2024 (2,960,000 ) October 31, 2024 (1,500,000 ) January 31, 2025 430,000
Schedule of Debt to APR Ratios [Table Text Block]	Maximum ARR Net Leverage Quarter Ending Ratio April 30, 2024 0.50 to 1.00 July 31, 2024 0.45 to 1.00 October 31, 2024 0.40 to 1.00 January 31, 2025 0.35 to 1.00
Schedule of Debt, Adjusted EBITDA [Table Text Block]	Maximum Debt to Adjusted EBITDA Quarter Ending Ratio April 30, 2025 3.50 to 1.00 July 31, 2025 3.00 to 1.00 October 31, 2025 2.50 to 1.00 January 31, 2026 and on the last day of each quarter thereafter 2.00 to 1.00

Note 9 - Related Party Transa_2

Note 9 - Related Party Transactions (Tables)	9 Months Ended
	Oct. 31, 2024
Notes Tables
Schedule of Related Party Transactions [Table Text Block]	Name of Investor Investment Amount Warrants Granted 121G, LLC (1) $ 1,000,000 59,829 Matthew W. Etheridge (2) 1,000,000 61,403 Jonathan R. Phillips (3) 50,000 2,991 The Ferayorni Family Trust (4) 500,000 29,914

Note 10 - Goodwill and Intang_2

Note 10 - Goodwill and Intangible Assets (Tables)	9 Months Ended
	Oct. 31, 2024
Notes Tables
Schedule of Goodwill [Table Text Block]	Nine Months Ended October 31, 2023 Balance as of January 31, 2023 $ 23,089,000 Impairment (9,813,000 ) Balance as of October 31, 2023 $ 13,276,000

Note 11 - Subsequent Events (Ta

Note 11 - Subsequent Events (Tables)	9 Months Ended
	Oct. 31, 2024
Notes Tables
Schedule of Debt, Adjusted EBITDA 1 [Table Text Block]	Maximum ARR Net Leverage Month Ending Ratio September 30, 2024 0.68 to 1.00 October 31, 2024 0.66 to 1.00 November 30, 2024 0.64 to 1.00 December 31, 2024 0.60 to 1.00 January 31, 2025 0.35 to 1.00 April 30, 2025 0.35 to 1.00
Schedule Of Minimum Adjusted EBITDA 1 [Table Text Block]	Minimum Month Ending Adjusted EBITDA September 30, 2024 $ (225,000 ) October 31, 2024 (500,000 ) November 30, 2024 (150,000 ) December 31, 2024 (100,000 ) January 31, 2025 and on the last day of each month thereafter through April 30, 2025 0

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation (Details Textual)			9 Months Ended
	Oct. 04, 2024	Jan. 31, 2024 USD ($)	Oct. 31, 2024 USD ($)
Number of Operating Segments			1
Number of Reportable Segments			1
Long-Term Debt		$ 9,066,000	$ 8,133,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	15
Adjustments to Additional Paid in Capital, Stock Split		(551,000)
Term Loan [Member]
Long-Term Debt			12,300,000
Long-Term Debt, Current Maturities		$ 1,500,000	$ 2,250,000

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies 1 (Details Textual)						3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 04, 2024 $ / shares shares	Jul. 18, 2024 $ / shares shares	May 07, 2024 USD ($)	Mar. 27, 2024 USD ($)	Oct. 16, 2023 USD ($)	Oct. 31, 2024 USD ($) shares	Jul. 31, 2024 USD ($)	Oct. 31, 2023 USD ($) shares	Oct. 31, 2024 USD ($) shares	Oct. 31, 2023 USD ($) shares	Jan. 31, 2023 USD ($)	Apr. 30, 2024	Feb. 07, 2024 USD ($)	Jan. 31, 2024 USD ($)
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability				$ 159,000
Business Combination, Contingent Consideration, Liability, Current						$ 377,000			$ 377,000					$ 1,794,000
Contract with Customer, Liability, Revenue Recognized						1,253,000			5,878,000
Revenue, Remaining Performance Obligation, Amount						30,068,000			30,068,000
Deferred Costs						68,000			68,000					77,000
Accumulated Amortization of Other Deferred Costs						147,000			147,000					102,000
Amortization of Deferred Charges						11,000		$ 24,000	44,000	$ 59,000
Deferred Commission Costs Paid and Payable						1,157,000			1,157,000					1,461,000
Amortization of Deferred Sales Commissions						141,000		129,000	450,000	383,000
Deferred Sales Commissions, Impairment Loss						93,000		35,000	93,000	35,000
Share-Based Payment Arrangement, Expense						451,000		517,000	$ 1,483,000	$ 1,626,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares									220,327	132,013
Restructuring and Related Cost, Number of Positions Eliminated					26
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent					24%
Restructuring Costs					$ 759,000		$ 0
Stock Issued						$ 41,000		$ 60,000	$ 109,000	$ 176,000
Professional Fees, Noncash									$ 4,000
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares						4,396		27,919	4,396	27,919
Restricted Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares						220,327		132,013	220,327	132,013
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares						237,027			237,027
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares) | shares						333		2,999	181,321	92,562
Restricted Stock [Member] | Director [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares) | shares		13,333
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures (in shares) | shares	6,666
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Payment Arrangement, Expense						$ 41,000		$ 60,000	$ 109,000	$ 176,000
Common Stock Warrant [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings						$ 0			$ 44,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3			$ 837,000
Minimum [Member] | Restricted Stock [Member] | Director [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Price (in dollars per share) | $ / shares	$ 26.25	$ 26.25
Common Stock Warrant [Member]
Warrants and Rights Outstanding													$ 881,000
Measurement Input, Exercise Price [Member] | Common Stock Warrant [Member]
Warrants and Rights Outstanding, Measurement Input			4.95									4.5	5.1
Measurement Input, Exercise Price [Member] | Common Stock Warrant [Member] | Minimum [Member]
Warrants and Rights Outstanding, Measurement Input						5.7			5.7
Measurement Input, Exercise Price [Member] | Common Stock Warrant [Member] | Maximum [Member]
Warrants and Rights Outstanding, Measurement Input						5.85			5.85
Measurement Input, Risk Free Interest Rate [Member] | Common Stock Warrant [Member] | Minimum [Member]
Warrants and Rights Outstanding, Measurement Input						0.04			0.04
Measurement Input, Risk Free Interest Rate [Member] | Common Stock Warrant [Member] | Maximum [Member]
Warrants and Rights Outstanding, Measurement Input						0.05			0.05
Measurement Input, Price Volatility [Member] | Common Stock Warrant [Member] | Minimum [Member]
Warrants and Rights Outstanding, Measurement Input						0.91			0.91
Measurement Input, Price Volatility [Member] | Common Stock Warrant [Member] | Maximum [Member]
Warrants and Rights Outstanding, Measurement Input						0.92			0.92
Term Loan and Revolving Line of Credit [Member]
Debt Instrument, Basis Spread on Variable Rate									1.50%
Debt Instrument, Basis Rate Floor									3.25%
Debt Instrument, Increase (Decrease) in Basis Spread on Variable Rate									0.50%
Debt Instrument, Unamortized Discount						$ 179,000			$ 179,000					193,000
Term Loan and Revolving Line of Credit [Member] | Fair Value, Inputs, Level 2 [Member]
Debt Instrument, Fair Value Disclosure						7,821,000			$ 7,821,000					$ 8,807,000
Private Placement Notes [Member]
Debt Instrument, Increase (Decrease) in Basis Spread on Variable Rate									0.98%
Debt Instrument, Unamortized Discount						33,000			$ 33,000
Private Placement Notes [Member] | Fair Value, Inputs, Level 2 [Member]
Debt Instrument, Fair Value Disclosure						4,096,000			4,096,000
Unsecured Subordinated Promissory Notes [Member]
Debt Instrument, Fair Value Disclosure						3,538,000			3,538,000
Debt Instrument, Unamortized Discount						862,000			862,000
Payments of Debt Issuance Costs											$ 20,000
Avelead Acquisition [Member]
Business Combination, Contingent Consideration, Liability, Current						$ 377,000			377,000
Avelead Acquisition [Member] | Common Stock [Member] | Second Earnout [Member]
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable									690,000
Avelead Acquisition [Member] | Warrant 1 [Member] | Second Earnout [Member]
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable									$ 881,000

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies 2 (Details Textual) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-11-01	Oct. 31, 2024
Revenue, Remaining Performance Obligation, Percentage	46%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Month)	12 months

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Fair Value of Liabilities (Details) - Fair Value, Recurring [Member]	Jan. 31, 2024 USD ($)	[1]
Acquisition earnout liability (1)	$ 1,794,000
Fair Value, Inputs, Level 1 [Member]
Acquisition earnout liability (1)	0
Fair Value, Inputs, Level 2 [Member]
Acquisition earnout liability (1)	0
Fair Value, Inputs, Level 3 [Member]
Acquisition earnout liability (1)	$ 1,794,000
[1]On March 27, 2024, the Company issued the shares of its common stock owed as part of the acquisition earnout liability related to the acquisition of Avelead Consulting, LLC (“Avelead”). The remaining obligation related to the acquisition earnout liability is to be settled in cash (refer to Note 3 – Business Combinations for more information). At that time, the acquisition earnout liability no longer qualified as a Level 3 fair value calculation and was removed from the hierarchy. As of that date, the Company recorded a valuation adjustment of $159,000 using the value of the shares issued adjusted for a discount for lack of marketability. As of April 30, 2024, the acquisition earnout liability no longer qualified as a Level 3 fair value calculation and was transferred out. See the table below for the roll-forward of values including the amount transitioned out of Level 3.

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Acquisition Earnout Liability Rollforward (Details) - Earn Out Liability [Member]	9 Months Ended
	Oct. 31, 2024 USD ($)
Beginning balance	$ 1,794,000
Settlement – common stock	(690,000)
Settlement – cash	(447,000)
Realized loss	159,000
Transfer out	(817,000)
Ending balance	$ 0

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2024	Oct. 31, 2023
Total revenues	$ 4,419,000	$ 6,133,000	$ 13,226,000	$ 17,235,000
Transferred over Time [Member]
Total revenues	4,419,000	6,133,000	13,091,000	17,161,000
Transferred at Point in Time [Member]
Total revenues	$ 0	$ 0	$ 135,000	$ 74,000

Note 2 - Summary of Significa_8

Note 2 - Summary of Significant Accounting Policies - Accounting Standards Update (Details) - USD ($)	9 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Allowance for credit losses	$ 86,000	$ 132,000
Allowance for credit losses, provision	(58,000)	0
Allowance for credit losses, writeoffs	31,000	0
Allowance for credit losses	59,000	96,000
Cumulative Effect, Period of Adoption, Adjustment [Member] | Accounting Standards Update 2016-13 [Member]
Allowance for credit losses	$ 0	$ (36,000)

Note 2 - Summary of Significa_9

Note 2 - Summary of Significant Accounting Policies - Schedule of Earnings Per Share (Details) - USD ($)		3 Months Ended						9 Months Ended
		Oct. 31, 2024	Jul. 31, 2024	Apr. 30, 2024	Oct. 31, 2023	Jul. 31, 2023	Apr. 30, 2023	Oct. 31, 2024	Oct. 31, 2023
Net loss		$ (2,476,000)	$ (2,803,000)	$ (2,739,000)	$ (11,911,000)	$ (2,515,000)	$ (2,901,000)	$ (8,018,000)	$ (17,327,000)
Net loss per common share – basic and diluted (in dollars per share)		$ (0.61)			$ (3.15)			$ (2.01)	$ (4.61)
Weighted average number of common shares – basic and diluted (in shares)	[1],[2]	4,055,268			3,780,689			3,981,406	3,756,420
[1]Diluted net loss per share excludes the effect of shares that are anti-dilutive. For the three and nine months ended October 31, 2024, diluted earnings per share excludes 4,396 outstanding stock options, 220,327 unvested restricted shares of common stock, and 237,027 shares of common stock issuable through the exercise of warrants. For the three and nine months ended October 31, 2023, diluted earnings per share excludes 27,919 outstanding stock options and 132,013 unvested restricted shares of common stock.[2]Includes the effect of vested and excludes the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of October 31, 2024 and 2023, there were 220,327 and 132,013 unvested restricted shares of common stock outstanding, respectively.

Note 2 - Summary of Signific_10

Note 2 - Summary of Significant Accounting Policies - Schedule of Restructuring Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Restructuring reserve	$ 74	$ 0
Restructuring charges	0	749
Restructuring payments	(74)	0
Restructuring reserve	0	749
Restructuring costs incurred	759
Expected restructuring costs	759
Employee Severance Allocated to Cost of Sales [Member]
Restructuring reserve	0	0
Restructuring charges	0	154
Restructuring payments	0	0
Restructuring reserve	0	154
Restructuring costs incurred	154
Expected restructuring costs	154
Employee Severance Allocated to Selling, General, and Administrative [Member]
Restructuring reserve	74	0
Restructuring charges	0	350
Restructuring payments	(74)	0
Restructuring reserve	0	350
Restructuring costs incurred	350
Expected restructuring costs	350
Employee Severance Allocated to Research and Development [Member]
Restructuring reserve	0	0
Restructuring charges	0	227
Restructuring payments	0	0
Restructuring reserve	0	227
Restructuring costs incurred	227
Expected restructuring costs	227
Employee Severance [Member]
Restructuring reserve	74	0
Restructuring charges	0	731
Restructuring payments	(74)	0
Restructuring reserve	0	731
Restructuring costs incurred	731
Expected restructuring costs	731
Professional Fees and Licenses [Member]
Restructuring reserve	0	0
Restructuring charges	0	18
Restructuring payments	0	0
Restructuring reserve	0	$ 18
Restructuring costs incurred	28
Expected restructuring costs	$ 28

Note 3 - Business Combination (

Note 3 - Business Combination (Details Textual) - USD ($)		3 Months Ended	9 Months Ended
	Mar. 27, 2024	Oct. 31, 2024	Oct. 31, 2024	Jan. 31, 2024
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.01	$ 0.01	$ 0.01
Business Combination, Contingent Consideration, Liability, Current		$ 377,000	$ 377,000	$ 1,794,000
Avelead Acquisition [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	105,958
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.01
Payments to Acquire Businesses, Gross		200,000	887,000
Business Combination, Contingent Consideration, Liability, Current		$ 377,000	$ 377,000
Avelead Acquisition [Member] | Earn Out Liability [Member]
Business Combination, Contingent Consideration, Liability				$ 1,794,000

Note 4 - Operating Leases (Deta

Note 4 - Operating Leases (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		18 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2024	Oct. 31, 2023	Mar. 31, 2023	Oct. 01, 2021	Aug. 16, 2021	Mar. 01, 2020
Membership Agreements and Daily Space Rentals [Member]
Operating Lease, Expense	$ 9,000	$ 6,000	$ 25,000	$ 16,000
Alpharetta Sublease [Member]
Lessor, Operating Lease, Term of Contract (Month)						18 months
Sublease Income	0	0	0	32,000	$ 292,000
Alpharetta Office Lease [Member]
Operating Lease, Right-of-Use Asset								$ 540,000
Lessee, Operating Lease, Discount Rate								6.50%
Operating Lease, Cost	0	0	0	32,000
Suwanee Office Lease [Member]
Operating Lease, Expense	$ 0	$ 0	$ 0	$ 6,000
Lessee, Operating Lease, Term of Contract (Month)							36 months
Lessee, Operating Lease, Renewal Term (Month)							12 months

Note 5 - Debt (Details Textual)

Note 5 - Debt (Details Textual)		3 Months Ended	9 Months Ended
	Nov. 29, 2022 USD ($)	Apr. 30, 2024 USD ($)	Oct. 31, 2024 USD ($) $ / shares	May 24, 2024 shares	Feb. 01, 2024 USD ($) shares	Jan. 31, 2024 USD ($)
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]	Prime Rate [Member]
Common Stock Warrant [Member]
Derivative Liability					$ 881,000
Professional Fees		$ 46,000
Maximum [Member]
Common Stock, Shares, Outstanding, Percent			9.99%
Non Directors and Officers [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 5.7
Directors and Officers [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 5.85
Securities Purchase Agreement February 2024 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares					267,728
Class of Warrant or Right, Securities Purchase Agreement February 2024 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares				267,728
Term Loan [Member]
Debt Instrument, Basis Spread on Variable Rate	1.50%
Debt Instrument, Basis Rate Floor	3.25%
Debt Instrument, Face Amount	$ 10,000,000
Debt Instrument, Term (Year)	5 years
Long-Term Debt, Maturity, Year Two			$ 500,000
Long-Term Debt, Maturity, Year Three			1,000,000
Long-Term Debt, Maturity, Year Four			2,000,000
Long-Term Debt, Maturity, Year Five			$ 3,000,000
Term Loan and Revolving Line of Credit [Member]
Debt Instrument, Basis Spread on Variable Rate			1.50%
Debt Instrument, Basis Rate Floor			3.25%
Debt Instrument, Covenant, Fixed Charge Coverage Ratio			1.2
Amortization of Debt Issuance Costs			$ 250,000
Debt Instrument, Unamortized Discount			179,000			$ 193,000
Unsecured Subordinated Promissory Notes [Member]
Debt Instrument, Face Amount			4,400,000
Debt Instrument, Interest Rate, Effective Percentage					15%
Debt Instrument, Fair Value Disclosure			3,538,000
Debt Instrument, Unamortized Discount			862,000
Debt Issuance Costs, Gross			$ 183,000
Unsecured Subordinated Promissory Notes [Member] | Securities Purchase Agreement February 2024 [Member]
Debt Instrument, Face Amount					$ 4,400,000
Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 2,000,000
Debt Instrument, Basis Spread on Variable Rate	1.50%
Debt Instrument, Basis Rate Floor	3.25%

Note 5 - Debt - Schedule of Out

Note 5 - Debt - Schedule of Outstanding Debt (Details) - USD ($)	Oct. 31, 2024	Jan. 31, 2024
Total	$ 8,133,000	$ 9,066,000
Total	4,129,000	0
Less: Current portion of notes payable	0	0
Non-current portion of notes payable	4,129,000	0
Revolving Credit Facility [Member]
Long term debt, gross	177,000	135,000
Notes payable and accrued interest	177,000	135,000
Note Payable [Member[
Long term debt, gross	4,907,000	0
Less: Deferred financing cost	(136,000)	0
Notes payable and accrued interest	4,907,000	0
Less: Discount on notes payable	(642,000)	0
Term Loan [Member]
Long term debt, gross	8,000,000	9,000,000
Total	12,300,000
Less: Current portion of term loan	(2,250,000)	(1,500,000)
Total non-current portion of debt	5,883,000	7,566,000
Notes payable and accrued interest	8,000,000	9,000,000
Term Loan and Revolving Line of Credit [Member]
Less: Deferred financing cost	(44,000)	(69,000)
Less: Discount on notes payable	$ (179,000)	$ (193,000)

Note 5 - Debt - Schedule of Min

Note 5 - Debt - Schedule of Minimum Adjusted EBITDA (Details) - USD ($)	Jan. 31, 2025	Oct. 31, 2024	Jul. 31, 2024	Apr. 30, 2024	Jan. 31, 2024
Minimum Adjusted EBITDA		$ (1,500,000)	$ (2,960,000)	$ (4,560,000)	$ (5,750,000)
Forecast [Member]
Minimum Adjusted EBITDA	$ 430,000

Note 5 - Debt - Schedule of Deb

Note 5 - Debt - Schedule of Debt to APR Ratio (Details)	3 Months Ended
	Jan. 31, 2025	Oct. 31, 2024	Jul. 31, 2024	Apr. 30, 2024
Debt to APR ratio		0.4	0.45	0.5
Forecast [Member]
Debt to APR ratio	0.35

Note 5 - Debt - Schedule of Adj

Note 5 - Debt - Schedule of Adjusted EBITDA Ratio (Details)	3 Months Ended
	Jan. 31, 2026	Oct. 31, 2025	Jul. 31, 2025	Apr. 30, 2025
Forecast [Member]
Adjusted EBITDA ratio	2	2.5	3	3.5

Note 6 - Income Taxes (Details

Note 6 - Income Taxes (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2024	Oct. 31, 2023	Jan. 31, 2024
Income Tax Expense (Benefit)	$ 0	$ (120,000)	$ 0	$ (59,000)
Effective Income Tax Rate Reconciliation, Percent			0%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			24%
Unrecognized Tax Benefits	$ 346,000		$ 346,000		$ 340,000

Note 7 - Equity (Details Textua

Note 7 - Equity (Details Textual) - USD ($)				3 Months Ended
	May 24, 2024	Feb. 06, 2024	Jun. 28, 2023	Apr. 30, 2024	Jun. 13, 2024
The 2024 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)					449,260
180 Consulting [Member]
Stock Issued During Period, Shares, New Issues (in shares)	37,647		26,275
Private Placement [Member]
Sale of Stock, Number of Shares Issued in Transaction (in shares)		17,543
Sale of Stock, Price Per Share (in dollars per share)		$ 5.7
Sale of Stock, Consideration Received on Transaction		$ 100,000
Net Proceeds from Issuance of Private Placement				$ 77,000
Proceeds from Issuance of Private Placement				81,000
Payments of Stock Issuance Costs				$ 4,000

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Details Textual) - 180 Consulting [Member] - Master Services Agreement [Member] - USD ($)	3 Months Ended		9 Months Ended		55 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2024
Stock Issued During Period, Shares, Issued for Services (in shares)	30,753	6,669	85,221	23,879	183,875
Professional Fees	$ 642,000	$ 639,000	$ 1,965,000	$ 2,558,000
Share-Based Payment Arrangement, Amount Capitalized	41,000	60,000	109,000	176,000
Payments for Other Fees	582,000	626,000	1,472,000	2,354,000
Statements of Work Under Sublease [Member]
Payments for Other Fees	$ 230,000	$ 87,000	$ 453,000	$ 468,000

Note 9 - Related Party Transa_3

Note 9 - Related Party Transactions (Details Textual) - USD ($)			3 Months Ended			9 Months Ended
	Feb. 07, 2024	Feb. 06, 2024	Oct. 31, 2024	Apr. 30, 2024	Oct. 31, 2023	Oct. 31, 2024	Oct. 31, 2023
Stock Issued During Period, Value, New Issues				$ 770,000
Matthew Etheridge [Member]
Related Party Transaction, Amounts of Transaction	$ 1,000,000
Matthew Etheridge [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		17,543
Shares Issued, Price Per Share (in dollars per share)		$ 5.7
Stock Issued During Period, Value, New Issues		$ 100,000
Rent Expense [Member] | Former Employee of Avelead [Member]
Related Party Transaction, Amounts of Transaction			$ 0		$ 0	$ 0	$ 6,000

Note 9 - Related Party Transa_4

Note 9 - Related Party Transactions - Schedule of Related Party Transactions (Details)	Feb. 07, 2024 USD ($) shares
Wyche Tee Green III [Member]
Related party transactions | $	$ 1,000,000	[1]
Wyche Tee Green III [Member] | Class of Warrant or Right, Securities Purchase Agreement February 2024 [Member]
Warrants Granted (in shares) | shares	59,829	[1]
Matthew Etheridge [Member]
Related party transactions | $	$ 1,000,000
Matthew Etheridge [Member] | Class of Warrant or Right, Securities Purchase Agreement February 2024 [Member]
Warrants Granted (in shares) | shares	61,403
Jonathan R Phillips [Member]
Related party transactions | $	$ 50,000	[2]
Jonathan R Phillips [Member] | Class of Warrant or Right, Securities Purchase Agreement February 2024 [Member]
Warrants Granted (in shares) | shares	2,991	[2]
Justin J Ferayorni [Member]
Related party transactions | $	$ 500,000	[3]
Justin J Ferayorni [Member] | Class of Warrant or Right, Securities Purchase Agreement February 2024 [Member]
Warrants Granted (in shares) | shares	29,914	[3]
[1]The securities held in the account of 121G, LLC (“121G”) may be deemed to be beneficially owned by Wyche “Tee” Green, III, the managing member of 121G. Mr. Green serves as Executive Chairman of the Company and is a member of the Company’s Board of Directors.[2]Mr. Phillips is a member of the Company’s Board of Directors.[3]The securities held in the account of The Ferayorni Family Trust may be deemed to be beneficially owned by Justin J. Ferayorni as co-trustee of The Ferayorni Family Trust. Mr. Ferayorni is a member of the Company’s board of directors.

Note 10 - Goodwill and Intang_3

Note 10 - Goodwill and Intangible Assets (Details Textual)	3 Months Ended		9 Months Ended
	Oct. 31, 2024 USD ($)	Oct. 31, 2023 USD ($)	Oct. 31, 2024 USD ($)	Oct. 31, 2023 USD ($)
Number of Reporting Units			1
Goodwill, Impairment Loss	$ 0	$ 9,813,000	$ 0	$ 9,813,000
Impairment, Long-Lived Asset, Held-for-Use	$ 0	$ 963,000	$ 0	$ 963,000

Note 10 - Goodwill and Intang_4

Note 10 - Goodwill and Intangible Assets - Summary of Goodwill (Details) - USD ($)	3 Months Ended		9 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2024	Oct. 31, 2023
Balance			$ 13,276,000	$ 23,089,000
Impairment	$ 0	$ (9,813,000)	0	(9,813,000)
Balance	$ 13,276,000	$ 13,276,000	$ 13,276,000	$ 13,276,000

Note 11 - Subsequent Events (De

Note 11 - Subsequent Events (Details Textual)	Nov. 20, 2024 USD ($)
Revolving Credit Facility [Member] | Subsequent Event [Member]
Proceeds from Lines of Credit	$ 1,000,000

Note 11 - Subsequent Events - S

Note 11 - Subsequent Events - Schedule of Debt to APR Ratio (Details)	1 Months Ended						3 Months Ended
	Apr. 30, 2025	Jan. 31, 2025	Dec. 31, 2024	Nov. 30, 2024	Oct. 31, 2024	Sep. 30, 2024	Jan. 31, 2025	Oct. 31, 2024	Jul. 31, 2024	Apr. 30, 2024
Debt to APR ratio								0.4	0.45	0.5
Forecast [Member]
Debt to APR ratio							0.35
Fifth Modification, Term Loan [Member] | Minimum [Member]
Debt to APR ratio			0.6	0.64	0.66	0.68
Fifth Modification, Term Loan [Member] | Minimum [Member] | Forecast [Member]
Debt to APR ratio	0.35	0.35
Fifth Modification, Term Loan [Member] | Maximum [Member]
Debt to APR ratio			1	1	1	1
Fifth Modification, Term Loan [Member] | Maximum [Member] | Forecast [Member]
Debt to APR ratio	1	1

Note 11 - Subsequent Events -_2

Note 11 - Subsequent Events - Schedule of Minimum Adjusted EBITDA (Details) - USD ($)	Apr. 30, 2025	Jan. 31, 2025	Dec. 31, 2024	Nov. 30, 2024	Oct. 31, 2024	Sep. 30, 2024	Jul. 31, 2024	Apr. 30, 2024	Jan. 31, 2024
Minimum Adjusted EBITDA					$ (1,500,000)		$ (2,960,000)	$ (4,560,000)	$ (5,750,000)
Forecast [Member]
Minimum Adjusted EBITDA		$ 430,000
Fifth Modification, Term Loan [Member]
Minimum Adjusted EBITDA					$ (500,000)	$ (225,000)
Fifth Modification, Term Loan [Member] | Forecast [Member]
Minimum Adjusted EBITDA	$ 0		$ (100,000)
Fifth Modification, Term Loan [Member] | Subsequent Event [Member]
Minimum Adjusted EBITDA				$ (150,000)